Since PA200 is highly expressed in lung adenocarcinoma, where T cell-associated markers are downregulated, Aaron Javitt et al. proposed that PA200 may affect tumor progression by modulating T cell-mediated antitumor immunity [88]. Here, PSME4 is linked to lung adenocarcinoma.